Brief: Abbisko Cayman Says U.S. FDA Granted Breakthrough Therapy Designation For Unit's Drug
30/01/2023 01:51
Jan 30 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* U.S. FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR
ABBISKO
THERAPEUTICS' CSF-1R INHIBITOR PIMICOTINIB
Source text for Eikon: ID:nHKS49qw3Z
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration